The aberrant transcriptional program of myeloid malignancies with poor prognosis: the effects of RUNX1 and TP53 mutations in AML

Myléne Gerritsen

    Research output: ThesisThesis fully internal (DIV)

    427 Downloads (Pure)


    Acute Myeloid Leukemia (AML) is the collective name for group of malignant clonal hematopoietic disorders that are highly heterogeneous, both clinically and biologically. In recent years, the implementation of novel techniques such as next-generation sequencing and SNP arrays has enabled better understanding of the somatic mutations underlying the myeloid malignancies. A broad spectrum of chromosomal abnormalities and genomic mutations has been identified, and combinations of various genetic defects can now be used as prognostic markers. This thesis focuses on understanding the underlying transcriptional programming of AMLs that have an adverse prognosis, in particular those with RUNX1 or TP53 gene mutations or features of ring sideroblasts.
    Original languageEnglish
    QualificationDoctor of Philosophy
    • Vellenga, Edo, Supervisor
    • Schuringa, Jan Jacob, Supervisor
    • Martens, J.H.A., Co-supervisor, External person
    • Stunnenberg, H.G., Assessment committee, External person
    • de Haan, Gerald, Assessment committee
    • van Vugt, M.A.T.M., Assessment committee, External person
    Award date4-Mar-2020
    Place of Publication[Groningen]
    Print ISBNs978-94-6375-764-5
    Electronic ISBNs978-94-6375-765-2
    Publication statusPublished - 2020

    Cite this